Sanofi-Aventis China Funds Clinical Practice Guideline Program For Hypertension
This article was originally published in PharmAsia News
Executive Summary
China recently kicked off a clinician practice guideline initiative, which will be adopted by the Chinese Medical Association. Hosted by the China International Medical Foundation and funded by Sanofi-Aventis China, one program will establish an expert panel to study the use of Irbesartan to control hypertension. To help physicians solve common clinical problems and raise the success rate of hypertension control, international and domestic academic exchanges will be held for Chinese cardiovascular-related experts. Meanwhile, China will conduct a survey on hypertension drug applications across the country. (Click here for more - Chinese Language)